Table 1 Fluid-based biomarker endpoint use per diagnostic group and trial phase. Percentage in N trials without (w/o) and with (w/) fluid-based biomarker endpoints of all 2,72 trials and percentage in N trials with fluid-based endpoints per phase. Due to rounding the percentages may not add up to 100%
Diagnostic group | N Trials w/o fluid-based endpoint | N Trials w/ fluid-based endpoint | N Trials w fluid-based endpoint | ||
|---|---|---|---|---|---|
Phase 1 | Phase 2 | Phase 3 + 4 | |||
Healthy participants | 32 (12%) | 7 (3%) | 6 (5%) | 1 (0.8%) | – |
Asymptomatic at risk | 4 (1%) | 9 (3%) | 1 (0.8%) | 4 (3%) | 4 (3%) |
Asymptomatic at risk to MCI due to AD | 1 (0.4%) | 0 (0%) | – | – | – |
Asymptomatic at risk to AD dementia | 1 (0.4%) | 4 (1%) | 1 (0.8%) | 3 (2%) | – |
MCI due to AD | 8 (3%) | 12 (4%) | 3 (2%) | 6 (5%) | 3 (2%) |
MCI due to AD to AD dementia | 42 (15%) | 40 (15%) | 11 (9%) | 25 (21%) | 4 (3%) |
AD dementia | 63 (23%) | 49 (18%) | 6 (5%) | 38 (31%) | 5 (4%) |